43
Views
15
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA

, , , , , , & show all
Pages 376-380 | Received 12 Jul 2006, Accepted 11 Sep 2006, Published online: 02 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (7)

Yohei Seto, Eiichi Tanaka, Eisuke Inoue, Ayako Nakajima, Atsuo Taniguchi, Shigeki Momohara & Hisashi Yamanaka. (2011) Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Modern Rheumatology 21:6, pages 579-593.
Read now
Akira Sagawa, Atsushi Fujisaku, Katsunori Ohnishi, Masaya Mukai, Izumi Yasuda, Yoshiharu Amasaki, Masato Shimizu, Kenji Ichikawa & Hirofumi Ohsaki. (2011) A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study). Modern Rheumatology 21:3, pages 251-257.
Read now
A Nakajima, E Inoue, E Tanaka, G Singh, E Sato, D Hoshi, K Shidara, M Hara, S Momohara, A Taniguchi, N Kamatani & H Yamanaka. (2010) Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scandinavian Journal of Rheumatology 39:5, pages 360-367.
Read now
Yuki Nanke, Masako Iwatani, Tsuyoshi Kobashigawa, Toru Yago, Hisashi Yamanaka & Shigeru Kotake. (2009) Radiographic repair in three Japanese patients with rheumatoid arthritis treated with bucillamine. Modern Rheumatology 19:6, pages 681-686.
Read now
Mikio Nakajima, Naoki Ueda, Hidetsugu Ohara, Muneaki Abe & Mitsuo Kinoshita. (2009) A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. Modern Rheumatology 19:4, pages 384-389.
Read now
Akiko Suda, Shouhei Nagaoka, Shigeru Ohono, Haruko Ideguchi, Takayoshi Soga & Yoshiaki Ishigatsubo. (2008) The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study. Modern Rheumatology 18:6, pages 609-614.
Read now

Articles from other publishers (8)

Tom E. Forshaw, Allen W. Tsang & Cristina M. Furdui. 2022. Redox Chemistry and Biology of Thiols. Redox Chemistry and Biology of Thiols 617 642 .
Kathryn M. Kingsmore, Amrie C. Grammer & Peter E. Lipsky. (2019) Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nature Reviews Rheumatology 16:1, pages 32-52.
Crossref
Chak Sing Lau, Faith Chia, Leonila Dans, Andrew Harrison, Tsu Yi Hsieh, Rahul Jain, Seung Min Jung, Mitsumasa Kishimoto, Ashok Kumar, Khai Pang Leong, Zhanguo Li, Juan Javier Lichauco, Worawit Louthrenoo, Shue Fen Luo, Rong Mu, Peter Nash, Chin Teck Ng, Bagus Suryana, Linda Kurniaty Wijaya & Swan Sim Yeap. (2019) 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. International Journal of Rheumatic Diseases 22:3, pages 357-375.
Crossref
Vivian P. Bykerk. 2015. Rheumatology. Rheumatology 434 442 .
Satoshi Ito. (2011) 6. Bucillamine and Gold (Gold Sodium Thiomalate and Auranofin).. Nihon Naika Gakkai Zasshi 100:10, pages 2936-2941.
Crossref
Yuki Nanke, Masako Iwatani, Tsuyoshi Kobashigawa, Toru Yago, Hisashi Yamanaka & Shigeru Kotake. (2009) Radiographic repair in three Japanese patients with rheumatoid arthritis treated with bucillamine. Modern Rheumatology 19:6, pages 681-686.
Crossref
Mikio Nakajima, Naoki Ueda, Hidetsugu Ohara, Muneaki Abe & Mitsuo Kinoshita. (2009) A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. Modern Rheumatology 19:4, pages 384-389.
Crossref
Akiko Suda, Shouhei Nagaoka, Shigeru Ohono, Haruko Ideguchi, Takayoshi Soga & Yoshiaki Ishigatsubo. (2008) The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study. Modern Rheumatology 18:6, pages 609-614.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.